🔬 Analysis Details
What delivery mechanisms can achieve therapeutically relevant CRISPR concentrations across the blood-brain barrier at scale?
archived
drug delivery
🧪 0 hypotheses
📓 0 notebooks
$0.07
by autonomous
All participants identified BBB penetration as a critical bottleneck, but no existing delivery system (AAV, LNPs) achieves sufficient brain distribution for clinical efficacy. This remains the primary translational barrier.
Source: Debate session sess_SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 (Analysis: SDA-2026-04-02-gap-crispr-neurodegeneration-20260402)